Collaboration between pharmaceutical companies and patient advocates often requires both parties to sign contracts covering various types of activities such as consultancy, collaborations, speaking engagements and advisory boards. These contracts define the terms and conditions of the engagements, covering such matters as confidentiality, intellectual property, copyright, data protection, compensation and other responsibilities of both parties. They typically also contain provisions, mandated by the pharmaceutical industry codes, designed to ensure an appropriate relationship between patient and pharmaceutical company. In the past, the complexity of these agreements has often been challenging for patient advocates to work with due to the contracts being long, difficult to understand and sometimes containing ambiguous clauses. Continue reading
Myeloma Patients Europe (MPE) held a webinar on reimbursement and Health Technology Assessment (HTA) given by Neil Bertelsen, Steering Committee member at Health Technology Assessment International (HTAi). Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on big data in hematology on Thursday 2 April 2020 from 18:00 – 19:00 CET. Continue reading
Myeloma Patients Europe (MPE) has put together an advice sheet for our members and myeloma patients on coronavirus (Covid-19). This advice has been reviewed by our scientific advisors and will be continually updated to reflect the latest information.
Myeloma Patients Europe (MPE) will hold a webinar on reimbursement and Health Technology Assessment (HTA) on Wednesday 18 March 2020 from 18:00 – 19:00 CET. Continue reading
Myeloma Patients Europe (MPE) held a webinar yesterday on myeloma and AL amyloidosis treatment update given by Dr Inger Nijhof, Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. Continue reading
As part of the educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM) 2020, which was cancelled due to the outbreak of the coronavirus infection, MPE is organising a Webinars series.
Myeloma Patients Europe (MPE) will hold a webinar on myeloma and AL amyloidosis treatment updates on Wednesday 11 March 2020 from 18:30 – 19:30 CET. Continue reading
Myeloma Patients Europe (MPE), in collaboration with the pharmaceutical company Amgen, launched a survey in 2019 for European myeloma patients to understand their treatment information needs. Continue reading
The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Continue reading